GCBP

Expanded Access Policy

For decades, GC Biopharma has been dedicated to discovering and developing safe and effective therapies for patients with rare diseases.

GC Biopharma is currently developing GC1130A, a potential enzyme replacement therapy for patients with Sanfilippo syndrome type A. We understand there may be interest in accessing investigational products outside of clinical trials. At this stage of clinical development, participation in a clinical study is the only way to access GC Biopharma’s investigational therapy.

We are committed to supporting patients with Sanfilippo syndrome type A and their families by striving to obtain regulatory approval to provide access to as many eligible patients as possible. As we gather more clinical data on the safety and efficacy of GC1130A, we will carefully review and update our Expanded Access Policy as needed to ensure it serves the best interests of patients.

For questions regarding GC Biopharma’s Expanded Access Policy, please email ExpandedAccess@gccorp.com. We aim to acknowledge inquiries within 5 business days. Please note that personal health information should not be included in your correspondence.